Paraoxonase 1 gene promoter polymorphisms are associated with the extent of stenosis in coronary arteries

Thrombosis Research

Volumn 123, Issue 3, 2009, Pages 503-510

  Najafi, Mohammad ^a   Gohari, Ladan Hosseani ^b   Firoozrai, Mohsen ^a  

^a IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b IRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Coronary Artery Disease; Haplotype; Paraoxonase1; Stenosis

Indexed keywords

ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE;

ADULT; AGED; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; CORONARY ARTERY OBSTRUCTION; DISEASE SEVERITY; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROMOTER REGION; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ARYLDIALKYLPHOSPHATASE; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; CORONARY STENOSIS; FEMALE; GENE FREQUENCY; GENOTYPE; HAPLOTYPES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK FACTORS;

EID: 57849144297     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.03.004     Document Type: Article

References (45)

1. Blatter Garin M.C., James R.W., Messmer S., Barja F., and Pometta D. Identification of a distinct human high-density lipoprotein subspecies defined by a lipoprotein-associated protein, K-45: identity of K-45 with paraoxonase. Eur J Biochem 211 (1993) 871-879
2. Jakubowski H. Calcium-dependent human serum homocysteine thiolactone hydrolase. A protective mechanism against protein N-homocysteinylation. J Biol Chem 275 (2000) 3957-3962
3. Sözmen E.Y., Mackness B., Sözmen B., Durrington P., Girgin F.K., Aslan L., et al. Effect of organophosphate intoxication on human serum paraoxonase. Hum Exp Toxicol 21 (2002) 247-252
4. Helbecque N., Cottel D., Codron V., Berr C., and Amouyel P. Paraoxonase 1 gene polymorphisms and dementia in humans. Neurosci Lett 358 1 (2004) 41-44
5. Azarsiz E., Kayikcioglu M., Payzin S., and Sözmen E.Y. PON1 activities and oxidative markers of LDL in patients with angiographically proven coronary artery disease. Int J Cardiol 91 (2003) 43-51
6. Kerridge I., Lincz L., Scorgia F., Hickey D., Granter N., and Spencer A. Association between xenobiotic gene polymorphisms and non-Hodgkin's lymphoma risk. Br J Haematol 118 (2002) 477-481
7. Selek S., Aslan M., Horoz M., Gur M., and Frel O. Oxidative status and serum PON1 activity in beta-Thalassemia minor. Clin Biochem 40 (2007) 287-291
8. Aviram M., Rosenblat M., Bisgaier C.L., Newton R.S., Primo-Parmo S.L., and La Du B.N. Paraoxonase inhibits high density lipoprotein (HDL) oxidation and preserves its functions a possible peroxidative role for paraoxonase. J Clin Invest 101 (1998) 1581-1590
9. Watson A.D., Berliner J.A., Hama S.Y., La Du B.N., Faull K.F., Fogelman M., et al. Protective effect of high-density lipoprotein associated paraoxonase inhibition of the biological activity of minimally oxidized low density lipoprotein. J Clin Invest 96 (1995) 2882-2891
10. Lusis A.L. Atherosclerosis. Nature 407 (2000) 233-241
11. Mackness B., Durrington P., McElduff P., Yarnell J., Azam N., Michael W., et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107 (2003) 2775-2779
12. Humbert R., Adler D.A., Disteche C.M., Haaet C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3 (1993) 73-76
13. Baum L., Ng H.K., Woo K.S., Tomlinson B., Rainer T.H., Chen X., et al. Paraoxonase 1 gene Q192R polymorphism affects stroke and myocardial infarction risk. Clin Biochem 39 (2006) 191-195
14. Leviev I., and James R.W. Promoter polymorphisms of human paraoxonase PON1 gene and serum paraoxonase activities and concentrations. Arterioscler Thromb Vasc Biol 20 (2000) 516-521
15. Mackness M., and Mackness B. Paraoxonase 1 and atherosclerosis: Is the gene of the protein more important?. Free Radical Bio Med 37 9 (2004) 1317-1323
16. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11,212 cases of coronary heart disease and 12,786 controls meta-analysis of 43 studies. Lancet 363 (2004) 689-695
17. Kadonaga J.T., Carner K.R., Masiarz F.R., and Tjian R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domian. Cell 51 (1987) 1079-1090
18. James R.W., Leviev I., Ruitz J., Passa P., Froguel P., and Blatter Garin M.C. Promoter polymorphism T(- 107)C and relative paraoxonase deficiency as determinants of risk of coronary artery disease. J Mol Med 79 (2001) 457-463
19. Judson R., Stephens J.C., and Windemuth A. The predictive power of haplotypes in clinical response. Pharmacogenomics 1 (2000) 15-26
20. Jarvik G.P., Hatsukami T.S., Carlson C., Richter R.J., Jampsa R., Brophy V.H., et al. Paraoxonase Activity, But Not Haplotype Utilizing the Linkage Disequilibrium Structure, Predicts Vascular Disease. Arterioscler Thromb Vasc Biol 23 (2003) 1465-1471
21. Blatter Garin M.C., James R.W., Dussoix P., Passa P., Froguel P., and Ruiz J. Paraoxonase polymorphism Met-Leu 54 is associated with modified serum concentration of the enzyme: a possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. J Clin Invest 99 (1997) 62-66
22. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
23. Frieldewald W.T., Levy R.I., and Fredrickson D.S. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentifuge. Clin Chem 18 (1972) 499-502
24. Gan K.N., Smolen A., Eckerson H.W., Wyte C.M., and La Du B.N. Purification of human serum paraoxonase/arylesterase. Drug Metab Dispos 19 (1991) 100-106
25. Miller S.A., Dykes D.D., and Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16 (1988) 1215
26. Najafi M., Firoozrai M., Gohari H.L., Zavarehie A., and Basiri G. Direct haplotyping of bi-allelic SNPs using Arms and RFLP analysis techniques. Biomol Engin 24 (2007) 609-612
27. Wang X., Fan Z., Huang J., Su S., Yu Q., Zhau J., et al. Extensive association analysis between polymorphisms of PON gene cluster with coronary heart disease in Chinese Han population. Arterioscler Thromb Vasc Biol 23 (2003) 328-334
28. Voetsch B., Benke K.S., Damasceno B.P., Siqueira L.H., and Loscalzo J. Paraoxonase 192 Gln-NArg polymorphism: an independent risk factor for nonfatal arterial ischemic stroke among young adults. Stroke 33 (2002) 1459-1464
29. Nevin D.N., Zambon A., Furlong C.E., Richter R.J., Humbert R., Hokanson J.E., et al. Paraoxonase genotypes, lipoprotein lipase activity, and HDL. Arterioscler Thromb Vasc Biol 16 10 (1996) 1243-1249
30. Pasdar A., Ross-Adams H., Cumming A., Cheung J., Whalley L., Clair D.S., et al. Paraoxonase gene polymorphisms and haplotype analysis in a stroke population. BMC Med Genet 7 (2006) 28
31. Rahmani M., Raiszadeh F., Allahverdian S., Kiaii S., Navab M., and Azizi F. Coronary artery disease is associated with the ratio of apolipoprotein A-1/B and serum concentration of lipoprotein B, but not with paraoxonase enzyme activity in Iranian subjects. Atherosclerosis 162 (2002) 381-389
32. Campoa S., Sardoa M.A., Trimarchib G., Bonaiutoa M., Fontanaa L., Castaldoa M., et al. Association between serum paraoxonase (PON1) gene promoter T(- 107)C polymorphism, PON1 activity and HDL levels in healthy Sicilian octogenarians. Exp Gerontol 39 (2004) 1089-1094
33. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., and Furlong C.E. Effects of 5-regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68 (2001) 1428-1436
34. Brophy V., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., and Furlong C.E. Promoter polymorphism effects on paraoxonase (PON1) expression. Am J Hum Genet 68 (2001) 1428-1436
35. Suehiro T., Nakamura T., Inoue M., Shinoki T., Ikede Y., Kumon Y., et al. A polymorphism upstream from the human paraoxonase (PON1) gene and its association with PON1 expression. Atherosclerosis 150 (2000) 295-298
36. Kerkeni M., Addad F., Chauffert M., Chuniaud L., Miled A., Trivin F., et al. Hyperhomocysteinemia, paraoxonase activity and risk of coronary artery disease. Clin Biochem 39 (2006) 821-825
37. James R.W., Leviev I., Ruiz J., Passa P., Froguel P., and Blatter Garin M.C. Promoter polymorphism T(- 107)C of the paraoxonase PON1 gene is a risk factor for coronary heart disease in type 2 diabetic patients. Diabetes 49 (2000) 1390-1393
38. James R.W., Leviev I., and Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in coronary artery disease patients. Circulation 101 (2000) 2252-2257
39. Sutherland W.H.F., Walker R.J., Jong S.A.D., Rij A.M.V., Phillips V., and Walker H.L. Reduced postprandial serum paraoxonase activity after a meal rich in used cooking fat. Arterioscler Thromb Vasc Biol 19 (1999) 1340-1347
40. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9 (1999) 745-753
41. Mackness B., Davies G.K., and Turkie W. Paraoxonase status in coronary heart disease. Are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
42. Granér M., Richard W., James R.W., Kahri J., Markku S., Nieminen M.S., et al. Association of paraoxonase-1 activity and concentration with angiographic severity and extent of coronary artery disease. J Am Col Cardiol 47 (2006) 2429-2435
43. Roest M., Jansen A.C.M., Barendrecht A., Leus F.R., Kastelein J.J.P., Hieronymus A.M., et al. Variation at the paraoxonase gene locus contributes to carotid arterial wall thickness in subjects with familial hypercholesterolemia. Clin Biochem 38 (2005) 123-127
44. Deakin S., Leviev I., Brulhart-Meynet M.C., and James R.W. Paraoxonase-1 promoter haplotypes and serum paraoxonase: a predominant role for polymorphic position - 107, implicating the Sp1 transcription factor. Biochem J 372 (2003) 643-649
45. Aviran M., and Rosenblat M. Paraoxonases and cardiovascular diseases: Pharmacological and nutritional influences. Curr Opin Lipidol 16 4 (2005) 393-399